Company intelligence / Profile preview
Ascelia Pharma AB
Malmö, Swedenascelia.com ↗
- Ownership
- Public · ACE
- Employees
- ~11
- Development stage
- Phase 3
01
Overview
Orviglance successfully met the primary endpoint in Phase 3 SPARKLE study, demonstrating significant improvement in visualization of focal liver lesions compared to unenhanced MRI. The company plans to submit NDA to FDA by mid-2025.
- Therapeutic areas
- OncologyNephrology
- Modalities
- Small moleculesOral contrast agents
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Ascelia Pharma AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ascelia Pharma AB.